Afimkibart
Afimkibart (PF-06480605; RVT-3101) is a humanized monoclonal antibody targeting TL1A (TNFSF15). Afimkibart blocks the TL1A‑DR3 signaling axis by neutralizing the TL1A ligand, inhibits the release of pro-inflammatory cytokines, suppresses NF-κB activation and IFN-γ production, and simultaneously attenuates fibroblast activation and fibrosis progression associated with this pathway. The Fc region of Afimkibart contains the mutations L234A, L235A, and G237A, which are designed to reduce the binding of the antibody to FcγR and C1q, thereby attenuating or eliminating the antibody’s ADCC and CDC effector functions. Afimkibart is applicable to research on immune inflammation-related conditions, such as ulcerative colitis.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
NF-κB |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[Afimkibart]
-
Synonyms
PF-06480605; RVT-3101
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)